Related references
Note: Only part of the references are listed.The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8 mg/week in patients with rheumatoid arthritis
Ryoko Sakai et al.
MODERN RHEUMATOLOGY (2011)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Treating rheumatoid arthritis to target: recommendations of an international task force
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Postmarketing Surveillance of the Safety and Effectiveness of Etanercept in Japan
Takao Koike et al.
JOURNAL OF RHEUMATOLOGY (2009)
The British Society for Rheumatology biologics register: 6 years on
K. L. Hyrich et al.
RHEUMATOLOGY (2008)
Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA:: results from the South Swedish Arthritis Treatment Group Register
L. E. Kristensen et al.
RHEUMATOLOGY (2008)
Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis
T. Takeuchi et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan
Toshihiro Matsui et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia - Associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy
F Wolfe et al.
ARTHRITIS AND RHEUMATISM (2006)
Predictors of infection in rheumatoid arthritis
MF Doran et al.
ARTHRITIS AND RHEUMATISM (2002)
Share Paper
